MUMBAI, India, June 30 -- Intellectual Property India has published a patent application (202621066687 A) filed by Satya Ranjan Dalai; and Vijendra Kumar on May 27, 2026, for Development And Qbd Optimization Of Extended-Release Matrix Tablet Of Telmisartan Using Hpmc And Ethyl Cellulose.
Inventors include Satya Ranjan Dalai; and Vijendra Kumar.
The application for the patent was published on June 26, 2026, under issue no. 26/2026.
Abstract: ABSTRACT TITLE: DEVELOPMENT AND QBD OPTIMIZATION OF EXTENDED-RELEASE MATRIX TABLET OF TELMISARTAN USING HPMC AND ETHYL CELLULOSE The present invention discloses an extended-release matrix tablet of Telmisartan (40 milligrams) employing hydroxypropyl methylcellulose (HPMC K4M) and ethyl cellulose as rate-controlling polymers for sustained drug delivery over 12 hours. A Quality by Design approach using factorial experimental design optimized the concentrations of HPMC and ethyl cellulose as critical formulation variables. Nine formulations were prepared by wet granulation and evaluated for pre-compression parameters, post-compression characteristics, in vitro dissolution, and drug release kinetics. The optimized formulation containing 30 milligrams HPMC K4M and 20 milligrams ethyl cellulose achieved 93.2 percent cumulative drug release at 12 hours following non-Fickian anomalous transport kinetics (Korsmeyer-Peppas n value of 0.525). Response surface methodology established the design space with R-squared of 0.9759. Accelerated stability studies at 40 degrees Celsius and 75 percent relative humidity for three months confirmed physicochemical stability. The invention provides a scalable extended-release Telmisartan formulation for improved hypertension management.
Disclaimer: Curated by HT Syndication.
